FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996989587> ?p ?o ?g. }

• W1996989587 endingPage "1446" @default.
• W1996989587 startingPage "1437" @default.
• W1996989587 abstract "What is the effect of different alkylating agents used without pelvic radiation to treat childhood cancer in girls on the ovarian reserve in survivors? Ovarian reserve seems to be particularly reduced in survivors who received procarbazine (in most cases for Hodgkin lymphoma) or high-dose chemotherapy; procarbazine but not cyclophosphamide dose is associated with diminished ovarian reserve. A few studies have demonstrated diminished ovarian reserve in survivors after various combination therapies, but the individual role of each treatment is difficult to assess. Prospective cross-sectional study, involving 105 survivors and 20 controls. One hundred and five survivors aged 17–40 years and 20 controls investigated on Days 2–5 of a menstrual cycle or Day 7 of an oral contraceptive pill-free interval. Main outcome measures: ovarian surface area (OS), total number of antral follicles (AFC), serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol and anti-Müllerian hormone (AMH). Survivors had a lower OS than controls: 3.5 versus 4.4 cm2 per ovary (P = 0.0004), and lower AMH levels: 10.7 versus 22 pmol/l (P = 0.003). Ovarian markers (OS, AMH, AFC) were worse in patients who received high-dose compared with conventional-dose alkylating agents (P = 0.01 for OS, P = 0.002 for AMH, P < 0.0001 for AFC). Hodgkin lymphoma survivors seemed to have a greater reduction in ovarian reserve than survivors of leukaemia (P = 0.04 for AMH, P = 0.01 for AFC), sarcoma (P = 0.04 for AMH, P = 0.04 for AFC) and other lymphomas (P = 0.04 for AFC). A multiple linear regression analysis showed that procarbazine but not cyclophosphamide nor ifosfamide dose was associated with reduced OS (P = 0.0003), AFC (P = 0.0007), AMH (P < 0.0001) and higher FSH levels (P < 0.0001). The small percentage of participating survivors (28%) from the total cohort does not allow conclusion on fertility issues because of possible response bias. The association between procarbazine and HL makes it impossible to dissociate their individual impacts on ovarian reserve. The number of controls is small, but ovarian volume and AMH levels in survivors were compared with published normal values and results were unchanged. Early detection and follow-up of compromised ovarian function after cancer therapy should help physicians to counsel young survivors about their fertility window. However, longitudinal follow-up is required to determine the rate of progression from low ovarian reserve to premature ovarian failure. La Ligue contre le Cancer (grant no., PRAYN7497). The authors have no competing interests to disclose." @default.
• W1996989587 created "2016-06-24" @default.
• W1996989587 creator A5015027188 @default.
• W1996989587 creator A5015606989 @default.
• W1996989587 creator A5018536511 @default.
• W1996989587 creator A5037551185 @default.
• W1996989587 creator A5041806820 @default.
• W1996989587 creator A5042088219 @default.
• W1996989587 creator A5046455089 @default.
• W1996989587 creator A5055874787 @default.
• W1996989587 creator A5067218613 @default.
• W1996989587 creator A5069253881 @default.
• W1996989587 creator A5070226523 @default.
• W1996989587 creator A5073782592 @default.
• W1996989587 creator A5078705132 @default.
• W1996989587 creator A5084206748 @default.
• W1996989587 date "2015-03-23" @default.
• W1996989587 modified "2023-10-18" @default.
• W1996989587 title "Ovarian reserve after treatment with alkylating agents during childhood" @default.
• W1996989587 cites W1970345239 @default.
• W1996989587 cites W1981750627 @default.
• W1996989587 cites W2005847738 @default.
• W1996989587 cites W2012876499 @default.
• W1996989587 cites W2022754720 @default.
• W1996989587 cites W2037548970 @default.
• W1996989587 cites W2045341652 @default.
• W1996989587 cites W2052334717 @default.
• W1996989587 cites W2052977110 @default.
• W1996989587 cites W2054868293 @default.
• W1996989587 cites W2061303983 @default.
• W1996989587 cites W2094867658 @default.
• W1996989587 cites W2101407679 @default.
• W1996989587 cites W2107518748 @default.
• W1996989587 cites W2107910796 @default.
• W1996989587 cites W2112309180 @default.
• W1996989587 cites W2126667745 @default.
• W1996989587 cites W2140264607 @default.
• W1996989587 cites W2140805687 @default.
• W1996989587 cites W2143608188 @default.
• W1996989587 cites W2144504411 @default.
• W1996989587 cites W2156329500 @default.
• W1996989587 cites W2160715479 @default.
• W1996989587 cites W2161226706 @default.
• W1996989587 cites W2163734837 @default.
• W1996989587 cites W2165986384 @default.
• W1996989587 cites W2167400693 @default.
• W1996989587 cites W2167910274 @default.
• W1996989587 cites W2171010262 @default.
• W1996989587 cites W2332118889 @default.
• W1996989587 doi "https://doi.org/10.1093/humrep/dev060" @default.
• W1996989587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25801499" @default.
• W1996989587 hasPublicationYear "2015" @default.
• W1996989587 type Work @default.
• W1996989587 sameAs 1996989587 @default.
• W1996989587 citedByCount "63" @default.
• W1996989587 countsByYear W19969895872016 @default.
• W1996989587 countsByYear W19969895872017 @default.
• W1996989587 countsByYear W19969895872018 @default.
• W1996989587 countsByYear W19969895872019 @default.
• W1996989587 countsByYear W19969895872020 @default.
• W1996989587 countsByYear W19969895872021 @default.
• W1996989587 countsByYear W19969895872022 @default.
• W1996989587 countsByYear W19969895872023 @default.
• W1996989587 crossrefType "journal-article" @default.
• W1996989587 hasAuthorship W1996989587A5015027188 @default.
• W1996989587 hasAuthorship W1996989587A5015606989 @default.
• W1996989587 hasAuthorship W1996989587A5018536511 @default.
• W1996989587 hasAuthorship W1996989587A5037551185 @default.
• W1996989587 hasAuthorship W1996989587A5041806820 @default.
• W1996989587 hasAuthorship W1996989587A5042088219 @default.
• W1996989587 hasAuthorship W1996989587A5046455089 @default.
• W1996989587 hasAuthorship W1996989587A5055874787 @default.
• W1996989587 hasAuthorship W1996989587A5067218613 @default.
• W1996989587 hasAuthorship W1996989587A5069253881 @default.
• W1996989587 hasAuthorship W1996989587A5070226523 @default.
• W1996989587 hasAuthorship W1996989587A5073782592 @default.
• W1996989587 hasAuthorship W1996989587A5078705132 @default.
• W1996989587 hasAuthorship W1996989587A5084206748 @default.
• W1996989587 hasBestOaLocation W19969895871 @default.
• W1996989587 hasConcept C126322002 @default.
• W1996989587 hasConcept C134018914 @default.
• W1996989587 hasConcept C142773365 @default.
• W1996989587 hasConcept C143998085 @default.
• W1996989587 hasConcept C2776600139 @default.
• W1996989587 hasConcept C2776694085 @default.
• W1996989587 hasConcept C2776755627 @default.
• W1996989587 hasConcept C2777688143 @default.
• W1996989587 hasConcept C2777904497 @default.
• W1996989587 hasConcept C2778324911 @default.
• W1996989587 hasConcept C2778575703 @default.
• W1996989587 hasConcept C2778780466 @default.
• W1996989587 hasConcept C2779112685 @default.
• W1996989587 hasConcept C2779234561 @default.
• W1996989587 hasConcept C2779429289 @default.
• W1996989587 hasConcept C2908647359 @default.
• W1996989587 hasConcept C29456083 @default.
• W1996989587 hasConcept C42407357 @default.
• W1996989587 hasConcept C518429986 @default.

• next